Fierce Pharma

NOVEMBER 6, 2023

History may repeat for Vertex Pharmaceuticals in the U.K., where a new decision by the country’s cost-effectiveness gatekeeper threatens to spark another dispute over the cost of lifesaving cystic | Last week, the U.K.'s National Institute for Health and Care Excellence unveiled draft guidance that acknowledged the effectiveness of Vertex’s cystic fibrosis drugs Trikafta, Symkevi and Orkambi.

Medicine 257

Medicine Pharmaceutical 257

MedCity News

NOVEMBER 6, 2023

People with obesity should be offered a range of suitable treatments as well: behavioral, nutrition, exercise, medication and surgery, through a coordinated and holistic approach under one roof, with a care coordinator. Like cancer, obesity is a heterogeneous disease and recommendations and responses to all treatment modalities will be heterogeneous as well.

Medical 114

Medical Biopharma 114

Fierce Pharma

NOVEMBER 6, 2023

At the start of its first-ever conference call to present its quarterly numbers, Krystal Biotech CEO Krish Krishnan was quick to point out that the company’s positive earnings for the third quarter | Krystal Biotech's launch of Vyjuvek, the world's first topical gene therapy, has been so promising that analysts with Evercore ISI increased their 2024 sales projection to $273 million.

Sales 246

Sales FDA 246

MedCity News

NOVEMBER 6, 2023

Celldex drug barzolvolimab has mid-stage results in a chronic inflammatory skin disease that top those of an approved Genentech drug and two experimental Novartis therapies. The biotech is preparing to advance its drug to Phase 3 testing in 2024.

Pharma 112

Pharma Biopharma 112

Advertisement

Distribution

Fierce Pharma

NOVEMBER 6, 2023

As Vertex preps for exa-cel launch, exec touts 'very large' opportunity but tempers early expectations zbecker Mon, 11/06/2023 - 20:59

271

271

MedCity News

NOVEMBER 6, 2023

About half (47%) of nonelderly uninsured veterans will be eligible for Medicaid or subsidies through the ACA Marketplace in 2024, according to a new report from the Urban Institute.

108

108

MedCity News

NOVEMBER 6, 2023

It was expected that the Affordable Care Act would lead to many employers dropping health benefits, but that did not happen, a new report from the Employee Benefit Research Institute found.

Leads 106

Leads Insurance 106

Fierce Pharma

NOVEMBER 6, 2023

Following suit with other companies that produce COVID-19 vaccines, BioNTech has discovered demand for its Pfizer-partnered, omicron-adapted shot has not met expectations this fall and has had to a | BioNTech has slashed its estimate of 2023 revenue by 20%, now expecting it to reach 4 billion euros ($4.3 billion) versus its previous estimate of 5 billion euros ($5.4 billion).

Sales 211

Sales 211

MedCity News

NOVEMBER 6, 2023

Bristol Myers Squibb is expanding its scope in cancer by acquiring rights to a Phase 1-ready Orum Therapeutics program that brings a new twist to antibody drug conjugates. The deal is the latest business development move in the hot field of ADCs.

Biopharma 105

Biopharma Pharma 105

Fierce Pharma

NOVEMBER 6, 2023

When Astellas ponied up $4.9 billion for Iveric Bio earlier this year, the company had identified the promise of Iveric's geographic atrophy candidate, now approved as Izervay, as a future revenue | Astellas is counting on Izervay to deliver gains in a heated GA market clash against rival Apellis. Now, 2-year data show the drug's effects increase over time.

Marketing 164

Marketing 164

Advertisement

Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.

Safety

PharmaTech

NOVEMBER 6, 2023

Pharmaceutical Technology Europe® spoke with Ole Wiborg from Zerion Pharma, a Danish pharmaceutical development company, at the inaugural Start-Up Market on the show floor at CPHI Barcelona 2023.

Pharma 98

Pharma Pharmaceutical Marketing 98

Fierce Pharma

NOVEMBER 6, 2023

With revenue on the rise for its fast-working depression med Auvelity, Axsome Therapeutics is in the process of boosting its sales force with nearly 100 new hires. | The company plans to expand its Auvelity sales force from 162 to 260 reps by next quarter in an effort to reach some 18,000 new prescribers.

Sales 164

Sales 164

MedCity News

NOVEMBER 6, 2023

Hera Biotech, a San Antonio-based startup developing a nonsurgical diagnostic test for endometriosis, won the Pitch Perfect contest at MedCity News’ INVEST Digital Health conference. The average diagnostic delay for the endometriosis is eight years, driven in large part by the fact that the only method currently used to diagnose the disease is a surgical procedure.

89

89

European Pharmaceutical Review

NOVEMBER 6, 2023

A new medicine to treat adults with non-small cell lung cancer (NSCLC) with a rare mutation called KRAS G12C has been authorised by the UK Medicines and Healthcare products Regulatory Agency (MHRA). According to the MHRA, Mirati Therapeutics B.V.’s Krazati ® (adagrasib) can be used in this indication in individuals who have an advanced form of the disease, or it has spread to other parts of the body.

Medicine 89

Medicine Consulting Patients Medical 89

Advertisement

Planning on running clinical trials in Japan? How can you reliably supply these studies? Discover Catalent’s clinical supply packaging facility in Shiga, Japan. Strategically located between Tokyo and Osaka, and one of largest in Japan, this 6,000 square meter facility offers comprehensive services including primary and secondary clinical packaging and labelling, comparator sourcing, cold chain storage, local and global distribution, local language support and white glove service to support stud

Distribution

MedCity News

NOVEMBER 6, 2023

Discussions around healthcare’s workforce crisis usually center around providers’ lack of clinicians, but there’s a sweeping shortage of revenue cycle workers, too. In a new report, Experian Health surveyed 200 employees who are responsible for staffing the revenue cycle function at providers — every respondent said that staff shortages are having a significant negative impact on their organization’s ability to get paid for care and/or patient engagement.

Healthcare 88

Healthcare Healthcare Patients 88

European Pharmaceutical Review

NOVEMBER 6, 2023

The global cell line development industry is expected to value $4,674.8 million by 2033, according to a report by Future Market Insights. Total cell line product sales are expected to reach $3,124.4 million in 2023, with a predicted compound annual growth rate (CAGR) of 4.1 percent through the next decade. Advancements in biotechnology, pharmaceutical research, and biomanufacturing processes are key factors in driving the market, the author acknowledged.

Pharmaceutical research 88

Pharmaceutical research Marketing Government Pharmaceutical 88

PharmaTimes

NOVEMBER 6, 2023

The device successfully diagnosed COPD in patients with 90% accuracy - News - PharmaTimes

Patients 124

Patients 124

PharmExec

NOVEMBER 6, 2023

Healthcare organizations can lower their risk of drug diversion by strengthening staffing, employee training, and technology.

Healthcare 105

Healthcare Healthcare Training 105

Advertisement

Clinical research has entered a new era, one that requires real-time analytics and visualization to allow trial leaders to work collaboratively and to develop, at the click of a mouse, deep insights that enable proactive study management. Learn how Revvity Signals helps drug developers deliver clinical trial data insights in real-time using a fast and flexible data and analytics platform to empower data-driven decision-making.

Safety

PharmaVoice

NOVEMBER 6, 2023

Bioethics guru Arthur Caplan of NYU gives his outspoken and frank opinion on the industry’s minefield of ethical challenges.

Ethics 98

Ethics Leads Pharma 98

European Pharmaceutical Review

NOVEMBER 6, 2023

IZERVAY ( avacincaptad pegol intravitreal solution) induced a year-over-year reductions in the rate of geographic atrophy lesion growth in patients with geographic atrophy secondary to age-related macular degeneration (AMD) in a Phase III trial, Astellas Pharma has announced. The findings presented at the American Academy of Ophthalmology (AAO) 2023 Annual Meeting, revealed that the treatment continued to reduce the rate of geographic atrophy lesion growth for both every month and every-other-mo

Food and Drug Administration 77

Food and Drug Administration Safety Food Patients 77

PharmaTimes

NOVEMBER 6, 2023

The image helps researchers understand how heart muscles operate in disease - News - PharmaTimes

103

103

Copyright Clearance Center

NOVEMBER 6, 2023

The post A Look at Hachette v. Internet Archive appeared first on Copyright Clearance Center.

96

96

Advertisement

When selecting a clinical supply provider, consideration often focuses upon the manufacturing, packaging, storage and distribution capabilities available that will, at face-value, be sufficient to meet the needs of the sponsor and their trial. However, there are human-based and knowledge-driven factors that are often overlooked that go beyond these basic physical capabilities and are integral to the development and delivery of high performing clinical supply chains.

Specialization

Pharmaceutical Technology

NOVEMBER 6, 2023

GlobalData uncovers the leading innovators in rAAV production technology for the pharmaceutical industry.

Leads 89

Leads Pharmaceutical 89

pharmaphorum

NOVEMBER 6, 2023

UK patient data project reaches one million volunteers Phil.

Patients 96

Patients 96

Pharmaceutical Technology

NOVEMBER 6, 2023

Krazati received conditional marketing authorisation as a second-line treatment of KRAS-G12C mutated locally advanced or metastatic NSCLC.

Marketing 64

Marketing 64

pharmaphorum

NOVEMBER 6, 2023

Drug combos from AZ, Boehringer show promise in CKD Phil.

95

95

Advertisement

Clinical development organizations face a wide array of challenges when it comes to data, many of which can impact the operational effectiveness of their clinical trials. In this whitepaper, experts from Revvity Signals explore how solutions like TIBCO® Spotfire® enable better, more streamlined studies. The whitepaper also features a success story from Ambrx, a leading biopharmaceutical company, detailing how it has leveraged Spotfire to tackle data quality and collaboration challenges in clinic

Leads

Contrarian Sales Techniques

NOVEMBER 6, 2023

In the last quarter alone, businesses that revamped their sales strategies saw a staggering 34% increase in revenue, outpacing competitors who adhered to traditional methods. This statistic isn't just a number—it's a testament to the transformative power of innovative sales approaches in today's market. In an era where consumer behaviors shift as rapidly as the technologies they use, the ability to adapt sales tactics is not just advantageous—it's essential.

Sales 52

Sales Sales Strategy Retail CRM 52

PharmaTech

NOVEMBER 6, 2023

Dujuan Lu, PhD, global leader—E&L, SGS Health Sciences, talks about the differences in designing E&L testing for combination products vs. conventional pharmaceuticals.

Pharmaceutical 52

Pharmaceutical 52

Legacy MEDSearch

NOVEMBER 6, 2023

Trinity Capital Inc. (NASDAQ: TRIN ) (“Trinity”), a leading provider of diversified financial solutions to growth-stage companies, today announced the commitment of $25 million in growth capital to Neuros Medical, Inc., a bioelectric technology company focused on alleviating chronic post-amputation pain and restoring quality of life. Neuros Medical’s Altius System incorporates the company’s patented platform technology, On-Demand Bioelectric Nerve Block, which patients

Medical 52

Medical Recruitment Management Leads 52

Pharmaceutical Commerce

NOVEMBER 6, 2023

While there are still hurdles to overcome along the way, home healthcare could deliver better patient-centered cancer care, providing improved patient outcomes, enhanced quality of life, and reduced strain on resources.

Healthcare 52

Healthcare Healthcare Patients 52

Advertisement

As the development pipeline for new drugs continues to grow, biopharmaceutical companies are re-evaluating how to best manage and balance resources across an increasing number of development projects and complex clinical trials. There are two approaches that can be used to speed a drug from development to clinic faster: timeline compression and parallel processing, but only one that considers the benefits of integrating clinical supply into the overall drug development process.

Management